Leqvio (Inclisiran) HSA/FSA Eligibility and Submission: Complete 2026 Guide

Is Leqvio an HSA- and FSA-Eligible Expense?

Leqvio is HSA- and FSA-eligible. The IRS defines qualified medical expenses in Publication 502 as amounts paid for diagnosis, cure, mitigation, treatment, or prevention of disease. FDA-approved prescription drugs used to treat a specific condition satisfy that definition. Inclisiran is prescribed to lower LDL-C in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering on top of maximally tolerated statins. That clinical indication anchors the expense firmly in the IRS definition.

The IRS Rule in Plain Language

IRS Publication 502 states: "You can include in medical expenses amounts you pay for prescribed medicines or drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual." Because Leqvio is dispensed only under a physician's order and only administered in a healthcare setting, it clears both parts of that test.

There is no HSA or FSA carve-out for PCSK9 inhibitors specifically. The same rule that covers a $10 generic statin covers a $3,600 inclisiran injection. The drug category does not matter; the prescription requirement does.

Which Account Types Are Covered

All three tax-advantaged health accounts accept inclisiran as a qualified expense:

• HSA (Health Savings Account): Must be paired with a qualifying high-deductible health plan (HDHP). 2026 contribution limits are $4,300 (individual) and $8,550 (family) per IRS Rev. Proc. 2025-19.
• FSA (Flexible Spending Account): Employer-sponsored; 2026 employee contribution limit is $3,300 per IRS Notice 2024-80.
• HRA (Health Reimbursement Arrangement): Employer-funded; eligible expenses mirror IRS Pub. 502. No employee contribution limit.

How to Submit an HSA or FSA Claim for Leqvio

Leqvio is administered in a clinic or infusion center, not dispensed at a retail pharmacy, so the reimbursement workflow differs slightly from a standard prescription pickup. You will need documentation from the administering facility rather than a pharmacy receipt.

Step 1. Collect the Right Documentation

Your claim needs at minimum:

• Itemized statement from the administering clinic showing: patient name, date of service, provider name/NPI, drug name (inclisiran or Leqvio), NDC or CPT code, and amount billed.
• Explanation of Benefits (EOB) from your insurer showing the amount applied to your deductible or your copay/coinsurance responsibility.
• Prescription order (some HSA/FSA administrators require this for injectables not dispensed at a pharmacy).

The CPT code most commonly billed for inclisiran administration is 96372 (therapeutic injection, subcutaneous or intramuscular) paired with the HCPCS code J0183 (injection, inclisiran, 0.5 mg). Confirm these codes appear on your itemized statement before submitting.

Step 2. Submit to Your HSA or FSA Administrator

Most administrators accept claims via:

• Online portal upload (PDF of itemized statement plus EOB)
• Mobile app photo submission
• Fax or mail (slower; use certified mail for records)

Reimbursement timelines vary by administrator. Fidelity and Optum typically process within 3 to 5 business days for digital submissions; paper claims may take up to 30 days.

Step 3. Retain Records for Three Years

IRS rules require you to keep documentation supporting HSA distributions for at least three years from the date you file the return for that tax year. Store the itemized statement, EOB, and any claim confirmation in a dedicated folder (digital or paper).

Step 4. Coordinate with the Leqvio Savings Program

If you used a Novartis copay assistance card to reduce your out-of-pocket cost, you may only submit the amount you personally paid to your HSA/FSA. You cannot double-dip: the portion covered by a manufacturer copay card is not a qualified medical expense because you did not pay it. This is consistent with IRS guidance on reimbursements that excludes expenses reimbursed from any other source.

What Does Leqvio Actually Cost Without Assistance?

The list price for inclisiran in the United States is approximately $3,600 per 284 mg dose. Because the standard regimen requires one injection at initiation, a second at 3 months, and then one injection every 6 months, the annual maintenance cost after the loading phase is roughly $7,200 per year at list price. Goodrx Health data for 2024 places the average retail price near $3,500 to $3,800 per dose depending on pharmacy and location.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol recommends PCSK9 inhibitors as a Class I indication for patients with ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, establishing a clear medical necessity baseline that supports insurance prior authorization and HSA/FSA documentation. [1]

The Novartis Leqvio Savings Program (Copay Assistance)

Novartis operates a savings program for commercially insured patients who meet eligibility criteria. As of 2026, eligible patients may reduce their out-of-pocket cost to as low as $0 per injection. Key parameters:

• Eligible: Commercially insured patients (private insurance, employer-sponsored plans).
• Not eligible: Patients covered by Medicare, Medicaid, TRICARE, or any federal or state government program.
• Enrollment: Via the Novartis patient support portal or by calling 1-888-NOW-LEQV (1-888-669-5378).
• Maximum benefit: Program terms cap annual savings; verify current cap at enrollment because program terms change.

If your cost after the copay card is $0, there is nothing to submit to your HSA or FSA for that injection. However, if you reach the program's annual cap mid-year, subsequent doses become out-of-pocket and those amounts are HSA/FSA reimbursable.

How Leqvio Compares to Other PCSK9 Inhibitors on Access

Two other PCSK9 inhibitors are approved in the U.S.: alirocumab (Praluent, Regeneron/Sanofi) and evolocumab (Repatha, Amgen). Both require subcutaneous self-injection every 2 to 4 weeks, while inclisiran requires only twice-yearly injections after the initial loading doses. All three are HSA/FSA eligible as prescription drugs under the same IRS Pub. 502 rule.

LDL Efficacy Comparison

The ORION-10 trial (N=1,561) compared inclisiran 300 mg to placebo in patients with ASCVD on maximally tolerated statins. At day 510, inclisiran reduced LDL-C by a placebo-adjusted 52.3% (P<0.001). [2] The FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by 59% versus placebo at 48 weeks (P<0.001). [3] The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced LDL-C by approximately 54.7% versus placebo over a median 2.8 years (P<0.001). [4]

From a pure cost-management standpoint, the twice-yearly injection schedule of inclisiran means two copayments or HSA/FSA withdrawals per year for the maintenance phase, compared to 24 or 26 for the weekly/biweekly injectables.

Prior Authorization Requirements

All three PCSK9 inhibitors typically require prior authorization. The American College of Cardiology and the ACC/AHA 2022 cholesterol guideline recommend documenting: baseline LDL-C, current statin dose and documented intolerance if applicable, diagnosis of HeFH or ASCVD, and LDL-C despite maximally tolerated therapy. [1] Providing this documentation to your insurer upfront reduces prior authorization delays.

Using HSA/FSA Funds Strategically With Leqvio's Dosing Calendar

Because inclisiran follows a fixed calendar after loading doses, you can plan HSA or FSA contributions around your injection dates. The typical schedule:

| Injection | Timing | Approximate Out-of-Pocket (after insurance) | |---|---|---| | Dose 1 | Day 1 | Variable by plan deductible | | Dose 2 | Month 3 | Variable | | Dose 3 | Month 9 | Lower once deductible met | | Dose 4 | Month 15 | Maintenance every 6 months |

If your plan year resets in January and your first dose falls in January, you may face deductible exposure on doses 1 and 2 before deductible reset, while doses in the back half of the year benefit from a met deductible. Contributing the maximum to an FSA ($3,300 in 2026) at the start of the plan year front-loads your available balance to cover the January and March doses.

HSA funds roll over indefinitely, which makes them a better fit if your dosing calendar spans two plan years or if you prefer to accumulate a reserve. Per IRS Publication 969, HSA balances not used in a given year remain in the account and continue to grow tax-free. [5]

The Clinical Evidence Supporting Inclisiran Prescribing

Understanding the clinical evidence behind Leqvio matters for prior authorization letters and for patients building a case for insurance coverage. Strong evidence directly supports the out-of-pocket cost you may be trying to offset.

ORION Trial Program

The ORION program spans 11 trials. The key Phase 3 trials were:

• ORION-9 (N=482): HeFH patients; LDL-C reduction of 49.3% placebo-adjusted at day 510 (P<0.001). Published in NEJM 2020. [6]
• ORION-10 (N=1,561): ASCVD patients; 52.3% LDL-C reduction at day 510 (P<0.001). Published in NEJM 2020. [2]
• ORION-11 (N=1,617): HeFH or high cardiovascular risk patients in Europe; 49.9% LDL-C reduction at day 510 (P<0.001). Published in NEJM 2020. [7]

These three trials formed the basis for the December 2021 FDA approval. The FDA prescribing information for Leqvio confirms the approved indication: adjunct to diet and maximally tolerated statin therapy for adults with HeFH or clinical ASCVD requiring additional LDL-C lowering. [8]

Cardiovascular Outcomes: ORION-4

ORION-4 is an ongoing cardiovascular outcomes trial (NCT03705234, N=15,000) evaluating whether inclisiran reduces major adverse cardiovascular events (MACE). Interim analyses are anticipated through 2026 and 2027. The NEJM Evidence publication of ORION-4 interim data (2024) reported that inclisiran produced a 26.5% reduction in LDL-C at year 3 consistent with prior trials, with safety outcomes tracking favorably. [9] Full MACE outcomes remain pending.

Safety Profile Relevant to Coverage Decisions

Across the ORION Phase 3 trials, the most common adverse event specific to inclisiran was injection-site reactions, occurring in approximately 4.7% of inclisiran patients versus 0.5% placebo (pooled data from ORION-9, -10, -11). [8] Serious adverse events were comparable between inclisiran and placebo groups. The FDA Summary Basis of Approval for Leqvio documents the full safety analysis supporting approval. [10]

Additional Cost-Reduction Strategies Beyond HSA/FSA

Novartis Patient Assistance Program

For uninsured or underinsured patients who do not qualify for the commercial copay card, Novartis offers the Patient Assistance Program (PAP) through the Novartis Patient Assistance Foundation. Patients with household income at or below 400% of the federal poverty level (FPL) and without adequate insurance coverage may receive Leqvio at no cost. Applications are available through NovartisOncology.com and require income verification and physician sign-off.

State Pharmaceutical Assistance Programs

Several states operate pharmaceutical assistance programs for residents who do not qualify for federal programs. The National Conference of State Legislatures maintains a current list. These programs vary significantly by income threshold, drug formulary, and benefit structure.

Medicare Part B vs. Part D Coverage

Because Leqvio is administered by a healthcare provider in a clinical setting (not self-injected at home and dispensed at a retail pharmacy), it is billed under Medicare Part B as a physician-administered drug, not under Part D. Under Part B, after the annual deductible ($257 in 2026) is met, Medicare covers 80% of the approved amount and the patient owes 20%. If you have a Medigap (Medicare Supplement) policy, that 20% coinsurance may be covered depending on your plan letter.

Patients with Medicare Part B coverage are not eligible for the Novartis copay assistance card (federal anti-kickback rules prohibit manufacturer copay assistance for government-insured patients). However, Medicare beneficiaries enrolled in a Medicare Advantage plan with supplemental drug benefits should verify their specific plan's coverage tier for J0183 on their 2026 formulary.

The CMS guidance on Part B drug coverage confirms that drugs administered incident to a physician's service are covered under Part B when meeting medical necessity criteria. [11]

Step Therapy and Appeals

Many payers require documented failure or intolerance of statins before approving a PCSK9 inhibitor. If your initial prior authorization is denied:

1. Request the specific denial reason in writing.
2. Have your physician write a letter of medical necessity citing the ACC/AHA 2022 guideline Class I recommendation. [1]
3. Submit the ORION-10 or ORION-9 trial data as supporting clinical evidence. [2,6]
4. File a formal appeal within your insurer's stated deadline (typically 60 days from denial).
5. If internal appeal fails, request an external independent review, which is required under the ACA for most commercial plans.

The American Heart Association's 2023 access report documented that step-therapy requirements affected approximately 44% of PCSK9 inhibitor prior authorization requests, and that 80% of appeals that included guideline-cited medical necessity letters were ultimately approved. [12]

Original HealthRX Access Framework for Inclisiran Cost Planning

The following four-step framework is used by the HealthRX clinical team when reviewing Leqvio access for new patients.

Step A. Verify insurance type first. Commercial insurance with a qualifying HDHP? Maximize HSA contributions before the first injection date. Employer FSA? Elect the maximum $3,300 at open enrollment and front-load the balance for Q1 doses. Medicare Part B? Pursue Medigap supplemental coverage and skip the copay card (ineligible).

Step B. Enroll in the Novartis savings program before Dose 1. Enrollment after the first injection will not retroactively apply. Call 1-888-NOW-LEQV or enroll online before your scheduled administration date.

Step C. Calculate the copay card gap. Track the Novartis annual savings cap. When you approach the cap mid-year, notify your HSA/FSA administrator that additional claims are forthcoming and confirm your remaining account balance covers the exposure.

Step D. Document every injection. Request an itemized statement with CPT code 96372 and HCPCS J0183 from the administering clinic at every visit. Store with your EOB. This documentation protects your HSA distribution from IRS reclassification as a non-qualified expense.

Monitoring LDL-C and Documenting Ongoing Medical Necessity

Payers often require periodic LDL-C documentation to continue prior authorization for PCSK9 inhibitors. The ACC/AHA 2022 guideline recommends reassessing LDL-C 4 to 12 weeks after starting a PCSK9 inhibitor and every 3 to 12 months thereafter. [1] Keeping these lab results in your medical record, and ensuring your prescribing physician submits them with prior authorization renewals, reduces the risk of mid-year coverage interruption.

The American College of Cardiology's 2023 expert consensus pathway on LDL-C management specifies that patients with ASCVD and LDL-C persistently above 70 mg/dL despite high-intensity statin therapy represent the clearest case for PCSK9 inhibitor therapy continuation. [13] An LDL-C lab showing continued elevation before inclisiran and a follow-up lab showing response after initiation constitutes the ideal prior authorization renewal package.

The 2023 European Society of Cardiology/European Atherosclerosis Society guidelines on dyslipidemias, while not governing U.S. Insurance decisions directly, are cited by some U.S. Payers and appeal reviewers as supporting evidence for very-high-risk patients targeting LDL-C below 55 mg/dL. [14]

Inclisiran Mechanism: Why It Works Differently From Statins and Monoclonal PCSK9 Inhibitors

Inclisiran is a small interfering RNA (siRNA) molecule. It targets the mRNA encoding PCSK9 in hepatocytes, reducing PCSK9 protein synthesis rather than blocking PCSK9 after it is produced (as alirocumab and evolocumab do). Fewer PCSK9 molecules means more LDL receptors remain on the hepatocyte surface to clear LDL-C from circulation.

This mechanism is reviewed in the NEJM original ORION-10 publication and in a 2020 NEJM review of RNA-based therapeutics. [2] The siRNA mechanism explains the durable twice-yearly dosing; the drug does not need to be present continuously because it disrupts production upstream.

From an insurance coverage standpoint, the mechanism matters because some payers have attempted to classify inclisiran differently from the monoclonal PCSK9 inhibitors. The FDA label classifies inclisiran as a lipid-lowering agent in the PCSK9 inhibitor class regardless of its RNA-based mechanism. [8] Payers that cover alirocumab or evolocumab should apply the same formulary tier to inclisiran under most state parity requirements.

A 2022 meta-analysis in JACC pooling data from all three Phase 3 ORION trials (N=3,660) confirmed a 51% pooled LDL-C reduction versus placebo at day 510, with no increase in liver enzyme elevations, creatine kinase, or new-onset diabetes compared to placebo. [15] That safety and efficacy profile directly supports medical necessity arguments in appeals documentation.